At a glance
- Originator IVAX Drug Research Institute
- Class Antiemetics; Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Muscarinic M3 receptor antagonists; Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cognition disorders; Nausea and vomiting
Most Recent Events
- 26 Oct 1999 IVAX Corporation has acquired the Institute for Drug Research